Distinct effects of calorie restriction on adipose tissue cytokine and angiogenesis profiles in obese and lean mice

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Kurki, Eveliina ^a   Shi, Jin ^a   Martonen, Essi ^a   Finckenberg, Piet ^a   Mervaala, Eero ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

adipose tissue; angiogenesis; calorie restriction; cytokines

Indexed keywords

ANGIOGENIN; COMPLEMENT COMPONENT C5A; CXCL16 CHEMOKINE; CYTOKINE; DPPIV PROTEIN; ENDOGLIN; ENDOSTATIN; ENDOTHELIN 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 16; INTERLEUKIN 2; LEPTIN; MIG PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANTES; SOMATOMEDIN BINDING PROTEIN 3; STROMELYSIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CALORIC RESTRICTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID DIET; LOW FAT DIET; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN MICROARRAY;

MUS;

EID: 84862980933     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-64     Document Type: Article

References (54)

1. Obesity as a medical problem. Kopelman PG, Nature 2000 404 635 643 10766250 (Pubitemid 30205068)
2. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Bays HE, Gonzlez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR, Expert Rev Cardiovasc Ther 2008 6 343 368 10.1586/14779072.6.3.343 18327995
3. Adipocytes as regulators of energy balance and glucose homeostasis. Rosen ED, Spiegelman BM, Nature 2006 444 847 853 10.1038/nature05483 17167472 (Pubitemid 46024991)
4. Adipokines in inflammation and metabolic diseases. Ouchi N, Parker JL, Lugus JJ, Walsh K, Nat Rev Immunol 2011 11 85 97 10.1038/nri2921 21252989
5. Adipose tissue macrophages: their role in adipose tissue remodeling. Suganami T, Ogawa Y, J Leukoc Biol 2010 88 33 39 10.1189/jlb.0210072 20360405
6. Adipose tissue dysfunction in obesity, diabetes and vascular diseases. Hajer GR, van Haeften TW, Visseran FLJ, Eur Heart J 2008 29 2959 2971 10.1093/eurheartj/ehn387 18775919
7. Angiogenesis and development of adipose tissue. Christiaens V, Lijnen HR, Mol Cell Endocrinol 2010 318 2 9 10.1016/j.mce.2009.08.006 19686803
8. Vascular targeting of adipose tissue as an anti-obesity approach. Daquinag AC, Zhang Y, Kolonin MG, Trends Pharmacol Sci 2011 32 300 307 10.1016/j.tips.2011.01.004 21349592
9. Adipose tissue remodelling and obesity. Sun K, Kusminski CM, Scherer PE, J Clin Invest 2011 6 2094 2101
10. Vascular outgrowths from tissue explants embedded in fibrin or collagen gels: a simple in vitro model of angiogenesis. Montesano R, Mouron P, Orci L, Cell Biol Int Rep 1985 9 869 875 10.1016/S0309-1651(85)90107-9 2415260
11. Extracellular matrix components secreted by microvascular endothelial cells stimulate preadipocyte differentiation in vitro. Varzaneh FE, Shillabeer G, Wong KL, Lau DC, Metabolism 1994 43 906 912 10.1016/0026-0495(94)90275-5 8028517 (Pubitemid 24213313)
12. Angiogenic activity of adipose tissue. Silverman KJ, Lund DP, Zetter BR, Lainey LL, Shahood JA, Freiman DG, Folkman J, Barger AC, Biochem Biophys Res Commun 1988 153 347 352 10.1016/S0006-291X(88)81229-4 2454107
13. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Cao Y, Nat Rev Drug Discov 2010 9 107 115 10.1038/nrd3055 20118961
14. Adipose tissue mass can be regulated through the vasculature. Rupnick MA, Panigraphy D, Zhang C-Y, Dallabrida SM, Lowell BB, Langer R, Folkman MJ, Proc Natl Acad Sci U S A 2002 99 10730 10735 10.1073/pnas.162349799 12149466
15. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Bråkenhielm E, Cao R, Gao B, Angelin B, Cannon B, Parini P, Cao Y, Circ Res 2004 94 1579 1588 10.1161/01.RES.0000132745.76882.70 15155527 (Pubitemid 38856965)
16. Aging, adiposity, and calorie restriction. Fontana L, Klein S, JAMA 2007 297 986 994 10.1001/jama.297.9.986 17341713 (Pubitemid 46380237)
17. High dietary calcium reduces body fat content, digestibility of fat, and serum vitamin D in rats. Papakonstantinou E, Flatt WP, Huth PJ, Harris TB, Obes Res 2003 11 387 394 10.1038/oby.2003.52 12634435 (Pubitemid 41151626)
18. Effects of high calcium diet with different whey proteins on weight loss and weight re-gain in high-fat fed C57Bl/6J mice. Pilvi TK, Harala S, Korpela R, Mervaala EM, Br J Nutr 2009 102 337 341 10.1017/S0007114508199445 19622178
19. Pericellular proteases in angiogenesis and vasculogenesis. Van Hinsbergh VWM, Engelse MA, Quax PH, Arterioscler Thromb Vasc Biol 2006 26 716 728 10.1161/01.ATV.0000209518.58252.17 16469948 (Pubitemid 43732143)
20. Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array. Fenton JI, Nunez NP, Perkins SN, Hord NG, Hursting SD, Diabetes Obes Metab 2009 11 343 354 10.1111/j.1463-1326. 2008.00974.x 19267713
21. Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity. Wang Q, Perrard XD, Perrard JL, Mansoori A, Raya JL, Hoogeveen R, Smith CW, Ballantyne CM, Wu H, Atherosclerosis 2011 219 100 108 10.1016/j.atherosclerosis.2011.07.025 21824616
22. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE, Peterson CA, Kern PA, J Clin Endocrinol Metab 2011 96 1990 E1998 10.1210/jc.2011-1567 21994960
23. Biological action of leptin as an angiogenic factor. Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardẽa G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR, Science 1998 281 1683 1686 9733517 (Pubitemid 28435586)
24. Leptin stimulates ischemia-induced retinal neovasculazation: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Suganami E, Takagi H, Ohashi J, Suzuma K, Suzuma I, Oh H, Watanabe D, Ojima T, Suganami T, Fujio Y, Nakao K, Ogawa Y, Yoshimura N, Diabetes 2004 53 2443 2448 10.2337/diabetes.53.9.2443 15331557 (Pubitemid 39145601)
25. Leptin induces vascular permeability and synenergistically stimulates angiogenesis with FGF-2 and VEGF. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y, Proc Natl Acad Sci U S A 2001 98 6390 6395 10.1073/pnas.101564798 11344271 (Pubitemid 32488247)
26. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. OReilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JT, Olsen BR, Folkman J, Cell 1997 88 277 285 10.1016/S0092-8674(00)81848-6 9008168 (Pubitemid 28015876)
27. Angiogenic factors are elevated in overweight and obese individuals. Silha JV, Krsek M, Sucharda P, Murphy LJ, Int J Obes 2005 29 1308 1314 10.1038/sj.ijo.0802987 (Pubitemid 41679261)
28. The physiological role of endoglin in the cardiovascular system. Lpez-Novoa JM, Bernabeu C, Am J Physiol Heart Circ Physiol 2010 299 959 H974 10.1152/ajpheart.01251.2009 20656886
29. Endothelin-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes. Chou YC, Perng JC, Juan CC, Jang SY, Kwok CF, Chen WL, Fong JC, Ho LT, Biochem Biophys Res Commun 1994 202 688 693 10.1006/bbrc.1994.1985 8048938
30. Evidence that endothelin-1 (ET-1) inhibits insulin-stimulated glucose uptake in rat adipocytes mainly through ETA receptors. Lee YC, Juan CC, Fang VS, Hsu YP, Lin SH, Kwok CF, Ho LT, Metabolism 1998 47 1468 1471 10.1016/S0026-0495(98)90071-3 9867075 (Pubitemid 28565529)
31. Endothelin-1 induces lipolysis in 3T3-L1 adipocytes. Juan CC, Chang CL, Lai YH, Ho LT, Am J Physiol Endocrinol Metab 2005 288 1146 E1152 10.1152/ajpendo.00481.2004 15671081 (Pubitemid 40726801)
32. Effect of endothelin-1 on lipolysis in rat adipocytes. Juan CC, Chang LW, Huang SW, Chang CL, Lee CY, Chien Y, Hsu YP, Ho PH, Chen YC, Ho LT, Obesity 2006 14 398 404 10.1038/oby.2006.53 16648610 (Pubitemid 46219758)
33. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. van Harmelen V, Eriksson A, ström G, Wåhlen K, Näslund E, Karpe F, Frayn K, Olsson T, Andersson J, Rydèn M, Arner P, Diabetes 2008 57 378 386 18025413
34. Endothelin-1 stimulated human adipocytes lipolysis through the ETA receptor. Eriksson AKS, van Harmelen V, Stenson BM, ström G, Wåhle K, Laurencikiene J, Rydèn M, Int J Obes 2009 33 67 74 10.1038/ijo.2008.212
35. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Ferri C, Bellini C, Desideri G, Baldoncini R, Properzi G, Santucci A, De Mattia G, Exp Clin Endocrinol Diabetes 1997 105 38 40 9439913 (Pubitemid 27375984)
36. Pleiotropic functions of plasminogen activator inhibitor-1. Lijnen HR, J Thromb Haemost 2005 3 35 45 10.1111/j.1538-7836.2004.00827.x 15634264 (Pubitemid 41647113)
37. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I, Arterioscler Thromb Vasc Biol 2000 20 1150 1154 10.1161/01.ATV.20.4.1150 10764686 (Pubitemid 30207595)
38. Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice. Lijnen HR, Thromb Haemost 2005 93 816 819 15886793 (Pubitemid 40691535)
39. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor-1. Ma LF, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB, Diabetes 2004 53 336 346 10.2337/diabetes.53.2.336 14747283 (Pubitemid 38174548)
40. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Crandall DL, Quinet EM, Ayachi SE, Hreha AL, Leik CE, Savio DA, Juhan-Vague I, Alessi M-C, Arterioscler Thromb Vasc Biol 2006 26 2209 2215 10.1161/01.ATV.0000235605.51400.9d 16825598 (Pubitemid 44465713)
41. Tiplaxtinin impairs nutritionally induced obesity in mice. Lignen HR, Alessi MC, Frederix L, Collen D, Juhan-Vague I, Thromb Haemost 2006 96 731 737 17139366 (Pubitemid 44883812)
42. Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR, Diabetes 2002 51 1093 1101 10.2337/diabetes.51. 4.1093 11916931 (Pubitemid 34438355)
43. Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene activation. Maquoi E, Demeulemeester D, Voros G, Collen D, Lijnen HR, Thromb Haemost 2003 89 696 704 12669125 (Pubitemid 36456967)
44. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Lijnen HR, Maqui E, Hansen LB, Van Hoef B, Frederix L, Collen D, Arterioscler Thromb Vasc Biol 2002 22 374 379 10.1161/hq0302.104522 11884277 (Pubitemid 34218741)
45. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E, Tartare-Deckert S, J Biol Chem 2003 278 11888 11896 10.1074/jbc.M209196200 12529376 (Pubitemid 36800160)
46. Effect of matrix metalloproteinase inhibition on adipose tissue development. Demeulemeester D, Collen D, Lijnen HR, Biochem Biophys Res Commun 2005 329 105 110 10.1016/j.bbrc.2005.01.103 15721280 (Pubitemid 40255427)
47. Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Lijnen HR, Demeulemeester D, Van Hoef B, Collen D, Maquoi E, Thromb Haemost 2003 89 249 255 12574803 (Pubitemid 36227275)
48. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschop MH, Bruemmer D, J Clin Invest 2007 117 2877 2888 10.1172/JCI31986 17823662 (Pubitemid 47529618)
49. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Kiefer FW, Zeyda M, Collinger K, Pfau B, Neuhofer A, Weichhart T, Säemann MD, Geyeregger R, Schlederer M, Kenner L, Stulnig TM, Diabetes 2010 59 935 946 10.2337/db09-0404 20107108
50. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C, Roteller F, Mugueta C, Gil MJ, Cienfuegos JA, Salvador J, Fruhbeck G, J Clin Endocrinol Metab 2007 92 3719 3727 10.1210/jc.2007-0349 17595250 (Pubitemid 47435361)
51. Osteopontin expression in human and murine obesity: extensive local upregulation in adipose tissue by minimal systemic alterations. Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G, Stulnig TM, Endocrinology 2008 149 1350 1357 18048491 (Pubitemid 351397930)
52. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Deng L, Chen N, Li Y, Zheng H, Lei Q, Biochim Biophys Acta 2010 1806 42 49 20122997
53. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. Chen G, Lin S-C, Chen J, He L, Dong F, Xu J, Han S, Du J, Entman ML, Wang Y, J Am Soc Nephrol 2011 22 1876 1886 10.1681/ASN.2010080881 21816936
54. Increased serum CXCL16 level is a marker for acute coronary syndromes. Sun Y, Chang Z, Zhang S, Arctic Med Res 2008 39 332 337 10.1016/j.arcmed.2007. 11.009 (Pubitemid 351221149)